Records 1 - 4
| The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling.
Journal of the National Cancer Institute 2022 May .
Umemoto Kumiko, Yamamoto Hiroyuki, Oikawa Ritsuko, Takeda Hiroyuki, Doi Ayako, Horie Yoshiki, Arai Hiroyuki, Ogura Takashi, Mizukami Takuro, Izawa Naoki, Moore Jay A, Sokol Ethan S, Sunakawa
| The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
Journal of cancer research and clinical oncology 2021 Sep .
Kim Hana, Ahn Soomin, Kim Hongsik, Hong Jung Yong, Lee Jeeyun, Park Se Hoon, Park Joon Oh, Park Young Suk, Lim Ho Yeong, Kang Won Ki, Kim Kyoung-Mee, Kim Seung T
| Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
Cancer immunology, immunotherapy : CII 2020 Oct .
Zhang Wei, Shi Junping, Wang Yingying, Zhou Hongyuan, Zhang Zewu, Han Zhiqiang, Li Guanghao, Yang Bo, Cao Guangtai, Ke Yan, Zhang Ti, Song Tianqiang, QiangL
| Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
Cancer 2020 Feb .
Maynard Hannah, Stadler Zsofia K, Berger Michael F, Solit David B, Ly Michele, Lowery Maeve A, Mandelker Diana, Zhang Liying, Jordan Emmett, El Dika Imane, Kemel Yelena, Ladanyi Marc, Robson Mark E, O'Reilly Eileen M, Abou-Alfa Ghassan